Reaping the rewards

Drug discovery is the subject of unprecedented advances in genomics, combinatorial chemistry, ultra-high-throughput screening and information technology. These technologies promise to discover proprietary validated targets and chemical entities faster and more economically than before. Furthermore, the quality of drugs going into development might improve if profiling of drug candidates, performing in vitro substitute adsorption-distribution-metabolism-excretion (ADME)-toxicology and genotyping subjects in clinical studies, is undertaken at an earlier stage.